ALKS - アルケルメス （Alkermes plc） アルケルメスALKSのチャート
ALKSの企業情報
| symbol | ALKS |
|---|---|
| 会社名 | Alkermes plc （アルケルメス） |
| 分野（sector） | Health Care ヘルスケア |
| 産業（industry） | Major Pharmaceuticals |
| 業種 | バイオテクノロジ―_メディカルリサ―チ 医療関連（Health Care） |
| 概要 | 事業概要 アルケルメス(Alkermes plc.)(Alkermes Inc.)は統合されたバイオテクノロジー企業。同社は一般的な慢性疾患の治療のための医薬品の開発、製造と商品化に従事している。同社はアルコール依存症の治療薬｢VIVITROL｣の開発・製造・商品化、及び統合失調症と双極I型障害の治療薬｢RISPERDAL CONSTA｣の製造を行っている。同社の薬品パイプラインは中枢神経系（CNS）疾患、報酬障害、中毒、糖尿病と自己免疫疾患などの一般的な慢性疾患の治療のための徐放性注射剤と経口製品を含む。同社はマサチューセッツ州に１カ所の研究施設、オハイオ州に１カ所の商業生産施設を有している。平成23年9月、同社はアイルランドで事業活動を開始した。平成23年9月16日、同社はElan Corporation plc (Elan)の製剤と薬品製造事業ユニットであるエラン医薬品テクノロジーズ（EDT）と合併した。 アルケルメスはアイルランドのバイオ医薬品会社。依存症、統合失調症、うつ病など中枢神経障害の治療用製品の開発と商業化に従事。製品には統合失調症治療薬｢リスパダ―ル・コンスタ｣、多発性硬化症治療薬｢アムピラ｣、2型糖尿病治療薬徐放性剤｢ビデュリオン｣、アルコ―ル依存症治療薬｢ビビトロル｣などがある。 Alkermes plc is a fully integrated, global biopharmaceutical company developing innovative medicines in the fields of neuroscience and oncology. The company has a portfolio of proprietary commercial products focused on addiction and schizophrenia, and a pipeline of product candidates in development for schizophrenia, bipolar I disorder, neurodegenerative disorders, and cancer. Headquartered in Dublin, Ireland, Alkermes plc has an R&D center in Waltham, Massachusetts; a research and manufacturing facility in Athlone, Ireland; and a manufacturing facility in Wilmington, Ohio. |
| 本社所在地 | Connaught House 1 Burlington Road Dublin 02451 IRL |
| 代表者氏名 | Richard F. Pops リチャードF.ポップス |
| 代表者役職名 | Chairman of the Board Chief Executive Officer 取締役会長兼最高経営責任者 |
| 電話番号 | +353 1-772-8000 |
| 設立年月日 | 31959 |
| 市場名 | NASDAQ National Market System |
| ipoyear | 1991年 |
| 従業員数 | 2000人 |
| url | www.alkermes.com |
| nasdaq_url | https://www.nasdaq.com/symbol/alks |
| adr_tso | ― |
| EBITDA | EBITDA（百万ドル） 7.23400 |
| 終値（lastsale） | 44.45 |
| 時価総額（marketcap） | 6903759662.1 |
| 時価総額 | 時価総額（百万ドル） 6709.616 |
| 売上高 | 売上高（百万ドル） 122.547 |
| 企業価値(EV) | 企業価値(EV)（百万ドル） 6556.5 |
| 当期純利益 | 当期純利益（百万ドル） -119.76600 |
| 決算概要 | 決算概要 BRIEF: For the six months ended 30 June 2018 Alkermes Plc revenues increased 29% to $529.8M. Net loss decreased 15% to $95.2M. Revenues reflect Product sales net increase of 22% to $201.6M Research and development revenue increase from $1.5M to $37.1M. Lower net loss reflects Interest Income increase of 60% to $3.4M (income). Basic Earnings per Share excluding Extraordinary Items increased from -$0.73 to -$0.61. |
ALKSのテクニカル分析
ALKSのニュース
Alkermes Celebrates Employee Volunteerism Throughout 2022 2023/02/02 19:15:00 Wallstreet:Online
NORTHAMPTON, MA / ACCESSWIRE / February 2, 2023 / Alkermes is committed to improving the communities where we live and work. Check out this video to see some highlights of our employees'' volunteer work in 2022!View additional multimedia and more ESG …
How Is the Brain Affected by Alcohol? 2023/01/31 21:05:00 Accesswire
NORTHAMPTON, MA / ACCESSWIRE / January 31, 2023 / Alkermes As Dry January comes to an end, learn more about how alcohol dependence affects the brain in this animation. Also, if you have concerns about your drinking habits, this questionnaire may be of help: https://lnkd.in/e3wwmTKK View additional multimedia and more ESG storytelling from Alkermes on 3blmedia.com. Contact Info: Spokesperson: Alkermes Website: https://www.3blmedia.com/profiles/alkermes Email: info@3blmedia.com SOURCE: Alkermes
These strategies will help Alkermes plc (ALKS) succeed 2023/01/27 16:48:00 US Post News
Alkermes plc (NASDAQ:ALKS) closed Thursday at $28.50 per share, up from $28.34 a day earlier. While Alkermes plc has overperformed by 0.56%, investors are advised to look at stock chart patterns for technical insight. Within its last year performance, ALKS rose by 13.14%, with highs and lows ranging from $32.79 to $21.75, whereas the simple […]
Alkermes PT Raised to $42 at Jefferies 2023/01/17 19:32:04 Investing.com
https://www.investing.com/news/pro/alkermes-pt-raised-to-42-at-jefferies-432SI-2982164
Alkermes: Nemvaleukin Alfa Gets UK MHRA''s Innovation Passport Designation To Treat Mucosal Melanoma 2023/01/17 12:36:00 Finanz Nachrichten
LONDON (dpa-AFX) - Irish biopharmaceutical company Alkermes plc (ALKS) announced Tuesday that UK regulatory body, the Medicines and Healthcare products Regulatory Agency or MHRA, has granted an In…
Alkermes: 47% of Adults With Alcohol Use Disorder Sought Help Because of Family Encouragement 2022/12/08 19:32:00 Finanz Nachrichten
NORTHAMPTON, MA / ACCESSWIRE / December 8, 2022 / Alkermes:For some people living with alcohol dependence, families play a support role. In fact, 47% of adults who sought treatment did so because a…
47% of Adults With Alcohol Use Disorder Sought Help Because of Family Encouragement 2022/12/08 19:30:00 Accesswire
NORTHAMPTON, MA / ACCESSWIRE / December 8, 2022 / Alkermes: For some people living with alcohol dependence, families play a support role. In fact, 47% of adults who sought treatment did so because a family member expressed concern. If someone you know is living with alcohol dependence, your support matters. Learn more here . View additional multimedia and more ESG storytelling from Alkermes on 3blmedia.com. Contact Info: Spokesperson: Alkermes Website: http://www.alkermes.com/ Email: info@3blmedia.com SOURCE: Alkermes
Patient Advocacy at Alkermes 2022/12/06 19:00:00 Accesswire
NORTHAMPTON, MA / ACCESSWIRE / December 6, 2022 / Alkermes Originally published in Alkermes 2021 Corporate Responsibility We have developed and now manufacture and commercialize proprietary medicines for the treatment of alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder - disease areas with vulnerable patient populations who are often treated in public health and criminal justice settings where systemic inequities are pervasive. We champion approaches to treatment that recognize the multitude of factors that affect outcomes for patients, caregivers and communities, and are committed to patient and community engagement, disease education and awareness and advocacy for policies that support equitable access to treatment options. Patient advocacy and community engagement are core to our mission. Regular engagements with policymakers and leaders in the patient advocacy community allow us to better understand their perspectives and goals. Learnings from these interactions help to inform our business activities, including in respect to clinical trials, policy and advocacy.
Alkermes Celebrates Giving Tuesday With Volunteering Efforts 2022/12/01 19:55:00 Accesswire
NORTHAMPTON, MA / ACCESSWIRE / December 1, 2022 / This Giving Tuesday, we are thankful for the employees who take time to support people in our communities who are in need. 10+ years ago, we launched Alkermes in Action, an annual employee volunteer program designed to support volunteer efforts in the places we live and work. We were also grateful to have the opportunity to support organizations that share our goals related to diversity, inclusion and belonging. In 2022, this included NAACP, OUTbio, Wreaths Across America and 500 Women Scientists, among other organizations, all of which are doing important work to make our communities more inclusive. To learn more about our diversity, inclusion and belonging work, check out: https://www.alkermes.com/ View additional multimedia and more ESG storytelling from Alkermes on 3blmedia.com. Contact Info: Spokesperson: Alkermes Website: http://www.alkermes.com/ Email: info@3blmedia.com SOURCE: Alkermes
Alkermes plc: Alkermes to Participate in the BofA Securities 2022 Biotech SMID Cap Conference 2022/11/30 21:04:00 Finanz Nachrichten
DUBLIN, Nov. 30, 2022 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) announced today that management will participate in a fireside chat as part of the BofA Securities 2022 Biotech SMID Cap Conferenc…
Can you now get a good deal on Alkermes plc’s shares? 2022/09/01 13:48:00 US Post News
In Wednesday’s session, Alkermes plc (NASDAQ:ALKS) marked $23.67 per share, down from $24.25 in the previous session. While Alkermes plc has underperformed by -2.39%, investors are advised to look at stock chart patterns for technical insight. Within its last year performance, ALKS fell by -24.28%, with highs and lows ranging from $33.00 to $21.24, whereas […]
Investing in Alkermes plc (ALKS) might be a great opportunity, but the stock is a bit undervalued 2022/08/26 14:08:00 US Post News
A share of Alkermes plc (NASDAQ:ALKS) closed at $24.94 per share on Thursday, down from $25.21 day before. While Alkermes plc has underperformed by -1.07%, investors are advised to look at stock chart patterns for technical insight. Within its last year performance, ALKS fell by -18.63%, with highs and lows ranging from $33.00 to $21.24, […]
Alkermes Earns 2022 Best Place for Working Parents Designation 2022/08/17 14:00:01 CSRwire
For the all the working parents at Alkermes, we recognize that there is no greater responsibility than being present for your family.
Alkermes initiated at neutral at Piper Sandler as company in transition (NASDAQ:ALKS) 2022/08/16 15:01:09 Seeking Alpha
Piper Sandler has initiated Alkermes (ALKS) with a neutral rating saying that its atypical antipsychotic Lybalvi (olanzapine and samidorphan) will not achieve blockbuster status.The…
Looking Into Alkermes''s Return On Capital Employed 2022/07/28 15:46:14 Benzinga
According to data from Benzinga Pro, during Q2, Alkermes ''s (NASDAQ: ALKS ) reported sales totaled $276.22 million. Despite a 16.06% increase in earnings, the company posted a loss of $30.14 million. In Q1, Alkermes brought in $278.55 million in sales but lost $35.90 million in earnings. What Is ROCE? Earnings data without context is not clear and can be difficult to base trading decisions on. Return on Capital Employed (ROCE) helps to filter signal from noise by measuring yearly pre-tax profit relative to capital employed by a business. Generally, a higher ROCE suggests successful growth of a company … Full story available on Benzinga.com